Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
You must be a Standard 1 Year member to access this content.
Paul, Weiss, Rifkind, Wharton & Garrison advised Qualcomm. Davis Polk & Wardwell advised SSW Partners. Skadden, Arps, Slate, Meagher & Flom and Roschier advised Veoneer on...
You must be a Standard 1 Year member to access this content.
Covington & Burling and Gibson, Dunn & Crutcher advised Merck, while Ropes & Gray advised Acceleron. Skadden, Arps, Slate, Meagher & Flom represented Centerview Partners LLC...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Laronde on the deal. Laronde announced its $440 million Series B Financing to advance the development of its eRNA platform and a broad pipeline...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Cerevel Therapeutics on the deal. Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Repertoire Immune Medicines on the deal. Repertoire Immune Medicines announced the completion of its $189 million Series B financing. Joining Flagship Pioneering, Repertoire’s...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Aura Biosciences on the deal. Aura Biosciences announced the closing of its oversubscribed $80 million financing. The financing was led by Matrix Capital...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Rubius Therapeutics on the deal. Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
